Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Post time 2024-3-2 19:11:47

journal：Circulation

Authors：Brendon L. Neuen; Hiddo J.L. Heerspink; Priya Vart; Brian L. Claggett; Robert A. Fletcher; Clare Arnott; Julianna de Oliveira Costa; Michael O. Falster; Sallie-Anne Pearson; Kenneth W. Mahaffey; Bruce Neal; Rajiv Agarwal; George Bakris; Vlado Perkovic; Scott D. Solomon; Muthiah Vaduganathan

Published date：2024-2-6

DOI：10.1161/circulationaha.123.067584

PDF link：https://www.ahajournals.org/doi/ ... ATIONAHA.123.067584

Article link：http://dx.doi.org/10.1161/circulationaha.123.067584

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 2024-3-2 19:11:48

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2024-3-2 19:22:13

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AHA] Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today